Innovative Industrial Properties (IIPR) investor relations material

Executive summary

• Regulatory milestone achieved with cannabis rescheduling from Schedule I to III, benefiting medical operators and signaling federal progress for the industry.

• Diversified REIT with $2.5B invested capital, operating across cannabis and life sciences in 19 U.S. states, with 110 properties and over $1B in dividends paid since 2016.

• Raised $128 million in equity and debt capital year-to-date to strengthen the balance sheet and address upcoming bond maturity.

• Significant tenant defaults and lease terminations, especially with PharmaCann, 4Front Ventures, Gold Flora, and TILT Holdings, impacted results.

• Management disclosed substantial doubt about the ability to continue as a going concern due to $291.2 million in notes maturing May 2026 and insufficient liquidity to retire them at maturity.

Financial highlights

• Q1 2026 total revenues were $69.0 million, down 3.8% year-over-year from $71.7 million, mainly due to tenant defaults.

• AFFO for the quarter was $53.4 million, or $1.88 per share, down from $1.94 year-over-year.

• Net income attributable to common stockholders was $30.2 million ($1.02 per diluted share), nearly flat year-over-year.

• Liquidity as of March 31 was $176.6 million, including $89.1 million cash and $87.5 million in credit availability.

• Dividends per share (annualized): $7.60, up from $4.47 in 2020 (9% CAGR).

Outlook and guidance

• Management is actively evaluating refinancing or capital-raising options to address the May 2026 debt maturity.

• Substantial doubt remains about the ability to continue as a going concern if the notes are not refinanced or repaid.

• Life science and cannabis sectors both viewed as growth drivers, with opportunistic investment planned.

• New leases and tenant arrangements expected to go into effect by year-end 2026, pending diligence and licensing.

• Cannabis industry projected 8% CAGR from 2025–2030, with legal sales expected to reach $43B by 2030.